Del Rio A - Search Results

1

microRNA biogenesis pathway as a therapeutic target for human disease and cancer.

De Santa F, Iosue I, Del Rio A, Fazi F. De Santa F, et al. Among authors: del rio a. Curr Pharm Des. 2013;19(4):745-64. Curr Pharm Des. 2013. PMID: 23016856 Review.

2

A small-molecule targeting the microRNA binding domain of argonaute 2 improves the retinoic acid differentiation response of the acute promyelocytic leukemia cell line NB4.

Masciarelli S, Quaranta R, Iosue I, Colotti G, Padula F, Varchi G, Fazi F, Del Rio A. Masciarelli S, et al. Among authors: del rio a. ACS Chem Biol. 2014 Aug 15;9(8):1674-9. doi: 10.1021/cb500286b. Epub 2014 Jun 11. ACS Chem Biol. 2014. PMID: 24914804

3

Small Molecules Targeting the miRNA-Binding Domain of Argonaute 2: From Computer-Aided Molecular Design to RNA Immunoprecipitation.

Bellissimo T, Masciarelli S, Poser E, Genovese I, Del Rio A, Colotti G, Fazi F. Bellissimo T, et al. Among authors: del rio a. Methods Mol Biol. 2017;1517:211-221. doi: 10.1007/978-1-4939-6563-2_15. Methods Mol Biol. 2017. PMID: 27924485

4

Immunoproteasome in cancer and neuropathologies: a new therapeutic target?

Bellavista E, Andreoli F, Parenti MD, Martucci M, Santoro A, Salvioli S, Capri M, Baruzzi A, Del Rio A, Franceschi C, Mishto M. Bellavista E, et al. Among authors: del rio a. Curr Pharm Des. 2013;19(4):702-18. Curr Pharm Des. 2013. PMID: 23016859 Review.

5

Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Andreoli F, et al. Among authors: del rio a. Curr Pharm Des. 2013;19(4):578-613. doi: 10.2174/138161213804581918. Curr Pharm Des. 2013. PMID: 23016851 Free PMC article. Review.

6

Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

Bruzzone S, Parenti MD, Grozio A, Ballestrero A, Bauer I, Del Rio A, Nencioni A. Bruzzone S, et al. Among authors: del rio a. Curr Pharm Des. 2013;19(4):614-23. doi: 10.2174/138161213804581954. Curr Pharm Des. 2013. PMID: 23016857 Free PMC article. Review.

7

ADP-ribosylated proteins as old and new drug targets for anticancer therapy: the example of ARF6.

Dani N, Barbosa AJ, Del Rio A, Di Girolamo M. Dani N, et al. Among authors: del rio a. Curr Pharm Des. 2013;19(4):624-33. Curr Pharm Des. 2013. PMID: 23016858 Review.

8

Editorial: cross-talking metabolism and epigenetics in anti-cancer drug design.

Del Rio A. Del Rio A. Curr Pharm Des. 2013;19(4):529-31. Curr Pharm Des. 2013. PMID: 23016866 No abstract available.

9

Inhibition of human dyskerin as a new approach to target ribosome biogenesis.

Rocchi L, Barbosa AJ, Onofrillo C, Del Rio A, Montanaro L. Rocchi L, et al. Among authors: del rio a. PLoS One. 2014 Jul 10;9(7):e101971. doi: 10.1371/journal.pone.0101971. eCollection 2014. PLoS One. 2014. PMID: 25010840 Free PMC article.

10

A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.

Peserico A, Germani A, Sanese P, Barbosa AJ, Di Virgilio V, Fittipaldi R, Fabini E, Bertucci C, Varchi G, Moyer MP, Caretti G, Del Rio A, Simone C. Peserico A, et al. Among authors: del rio a. J Cell Physiol. 2015 Oct;230(10):2447-2460. doi: 10.1002/jcp.24975. J Cell Physiol. 2015. PMID: 25728514 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

499 results

Search Page